Comparison between Mahamaya Lifesciences IPO and Multiplier AI IPO.
Mahamaya Lifesciences IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Multiplier AI IPO is a SME Bookbuilding proposed to list at NSE SME.
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |
|---|---|---|
| Logo |  |  |
| Issue Category | SME | SME |
| Issue Type | IPO | IPO |
| Process Type | Bookbuilding | Bookbuilding |
| Listing At | BSE SME | NSE SME |
| Lead Managers | Oneview Corporate Advisors Pvt.Ltd. | Swastika Investmart Ltd. |
| Registrar | Kfin Technologies Ltd. | MUFG Intime India Pvt.Ltd. |
| Market Maker | Mansi Share & Stock Broking Pvt.Ltd. | |
| DRHP | DRHP  | DRHP |
| RHP | RHP | RHP |
| Final Prospectus | Final Prospectus | Final Prospectus |
| Anchor Investor | Anchor Investor | |
| IPO Allotment URL | IPO Allotment URL |
The total issue size of Mahamaya Lifesciences IPO is up to ₹66.91 Cr whereas the issue size of the Multiplier AI IPO is up to ₹0.00 Cr. The final issue price of Mahamaya Lifesciences IPO is ₹114.00 per share and of Multiplier AI IPO is .
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ₹108.00 per share | |
| Issue Price (Upper) | ₹114.00 per share | |
| Issue Price (Final) | ₹114.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | 1200 shares | |
| Fresh Issue Size | 53,29,200 shares | 35,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹60.75 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 5,40,000 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹6.16 Cr | up to ₹0.00 Cr |
| Issue Size Total | 58,69,200 shares | 35,00,000 shares |
| Issue Size Total (Amount) | up to ₹66.91 Cr | up to ₹0.00 Cr |
Mahamaya Lifesciences IPO opens on Nov 11, 2025, while Multiplier AI IPO opens on . The closing date of Mahamaya Lifesciences IPO and Multiplier AI IPO is Nov 13, 2025, and , respectively.
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |
|---|---|---|
| Anchor Bid Date | Nov 10, 2025 | |
| Issue Open | Nov 11, 2025 | |
| Issue Close | Nov 13, 2025 | |
| Basis Of Allotment (Tentative) | Nov 14, 2025 | |
| Initiation of Refunds (Tentative) | Nov 17, 2025 | |
| Credit of Share (Tentative) | Nov 17, 2025 | |
| Listing date (Tentative) | Nov 18, 2025 | |
| Anchor Lockin End date 1 | Dec 13, 2025 | |
| Anchor Lockin End date 2 | Feb 11, 2026 |
Mahamaya Lifesciences IPO P/E ratio is 15.65, as compared to Multiplier AI IPO P/E ratio of .
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Mahamaya Lifesciences Ltd.'s revenue increased by 64% and profit after tax (PAT) rose by 148% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 77.27 | 100 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 56.35 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 15.65 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹266.82 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 34.94% | 41.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 23.15% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 1.08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.29 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 26.19% | 41.90% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Mahamaya Lifesciences IPO Retail Individual Investors (RII) are offered 20,59,200 shares while in Multiplier AI IPO retail investors are offered 20,59,200 shares. Qualified Institutional Buyers (QIB) are offered 11,76,000 shares in Mahamaya Lifesciences IPO and in Multiplier AI IPO.
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |
|---|---|---|
| Anchor Investor Reservation | 17,52,000 shares | |
| Market Maker Reservation | 3,09,600 shares | |
| QIB | 11,76,000 shares | |
| NII | 8,82,000 shares | |
| RII | 20,59,200 shares | |
| Employee | 0 shares | |
| Others | ||
| Total | 58,69,200 shares |
Mahamaya Lifesciences IPO subscribed 1.63x in total, whereas Multiplier AI IPO subscribed .
| Mahamaya Lifesciences IPO | Multiplier AI IPO | |
|---|---|---|
| QIB (times) | 1.19x | |
| NII (times) | 3.63x | |
| Big NII (times) | 5.00x | |
| Small NII (times) | 0.90x | |
| RII (times) | 1.02x | |
| Employee (times) | ||
| Other (times) | ||
| Total (times) | 1.63x |
